The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

Eli Lily continues to dominate the weight loss market, willing to crush any competitor that threatens its dominance. One such ...

Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.

US: Sharing the topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial, Eli Lilly and Company ...

Meds like Wegovy are all over the news. But are they right for you, especially if you’re older than the average user?

The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...

They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to ...

Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...

NICE has accepted a request from NHS England to slow down the roll out of weight-loss drug tirzepatide but GP workload ...